Last updated
SLU-PP-332 and 5-Amino-1MQ both appear under the metabolic banner, and neither is a peptide — both are synthetic small molecules catalogued here for their metabolic relevance. They pursue fat loss and metabolic health by entirely different mechanisms: one activates a transcriptional program for oxidative metabolism, the other blocks an enzyme that depletes NAD+ precursors.
Both are preclinical, with the published data in rodents and no human trials. This comparison contrasts their mechanisms and research framing, not proven outcomes.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | SLU-PP-332 | 5-Amino-1MQ |
|---|---|---|
| What it is | A pan-ERR agonist — not a peptide | An NNMT inhibitor — not a peptide |
| Strategy | Activate the PGC-1α/ERR oxidative program | Inhibit NNMT to preserve NAD+ / methyl-donor pools |
| Direct target | Estrogen-related receptors ERRα/β/γ | Nicotinamide N-methyltransferase (NNMT) |
| Framing | “Exercise mimetic” — mitochondrial biogenesis, fat oxidation | Adipose metabolism, sarcopenia (muscle aging) |
| Reported effect | More oxidative muscle fiber, higher energy expenditure, less fat (mice) | Preserved NAD+/SAM pools, metabolic readouts in fat and muscle (mice) |
| Evidence stage | Preclinical | Preclinical |
| FDA approval | None | None |
SLU-PP-332 is a direct agonist of the estrogen-related receptors (ERRα/β/γ), the orphan nuclear receptors downstream of PGC-1α that govern mitochondrial biogenesis and fat oxidation. Activating them pharmacologically reproduces part of the transcriptional response to endurance exercise — the basis for calling it an “exercise mimetic.” In mice it increased oxidative muscle fiber and energy expenditure and reduced diet-induced obesity without changes in food intake.
5-Amino-1MQ works on a different lever entirely. It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide — consuming both a NAD+ salvage precursor and SAM, the cell’s main methyl donor. Blocking NNMT is studied to preserve those pools, with preclinical metabolic effects in adipose tissue and aging muscle. So the contrast is between switching on an oxidative transcriptional program (SLU-PP-332) and preventing the depletion of a metabolic cofactor (5-Amino-1MQ). Both are small molecules, not peptides, and both are preclinical with no human data.
Two metabolic small molecules, two mechanisms. SLU-PP-332 activates the ERR/PGC-1α oxidative program and is framed as an exercise mimetic; 5-Amino-1MQ inhibits NNMT to protect NAD+ and methyl-donor pools, with a focus on fat and muscle. Neither is a peptide, both are preclinical with rodent-only data, and neither is FDA-approved. This page is a research and educational reference.
SLU-PP-332 is a pan-ERR agonist that activates the PGC-1α/ERR program for mitochondrial biogenesis and fat oxidation — an “exercise mimetic.” 5-Amino-1MQ is an NNMT inhibitor studied to preserve NAD+ and methyl-donor pools. Different targets, different mechanisms.
No. Both are synthetic small molecules catalogued alongside peptides for their metabolic relevance; neither is a peptide.
No. The published work for both is in rodents; there are no human clinical trials or safety data.
No — both are preclinical research compounds and neither is FDA-approved. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between SLU-PP-332 and 5-Amino-1MQ — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.